Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
about
Review article: Why is there still a debate regarding the safety and efficacy of intravenous thrombolysis in the management of presumed acute ischaemic stroke? A systematic review and meta-analysis.Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials.Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled TrialsIntravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies.No space left for intravenous thrombolysis in acute stroke: CONS.Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.The evolution of recombinant thrombolytics: Current status and future directionsNovel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic StrokeIntravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.Unknown onset ischemic strokes in patients last-seen-well >4.5 h: differences between wake-up and daytime-unwitnessed strokes.The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke.New era of stroke therapy and new challenges.Generation and characterization of tissue-type plasminogen activator transgenic rats.Reperfusion therapy in acute ischemic stroke: dawn of a new era?Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke.A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset.
P2860
Q30248290-B2D3914B-DCEF-49EB-BAD8-8B99111CCBAAQ31122611-68195065-F50F-4128-89B2-7A0B09ED6ECBQ33644102-6DE21F89-FF87-4546-B5C2-4D18F7E20093Q36145434-892C43E4-4579-417F-8A2F-88E9C42781B7Q36956762-1A783BA0-12B1-4215-A339-D3EE545AE22FQ38381277-A47B8E63-1FD6-4840-80DD-758F9B2C3CE9Q38589822-690BF6EB-C696-436F-AB24-30A6C395E014Q38803641-834BEC61-E2EC-4042-8C98-FA8CC635AEC9Q38917550-27E0D763-93A5-466E-B0A0-04FD434D46BBQ39040401-B25FA620-F240-4639-86D8-9144E8297E43Q39394485-B97C2671-3E69-465C-8322-CE1CF1663C89Q41478342-0E317B69-2C9B-4D4C-8EFD-3F71551369E3Q42279127-934CCEC0-8DE5-43E2-B2A3-52D5A1A72E32Q42349562-CD68EDFB-2E86-4DBC-9C2E-3408D797CCCBQ46255586-F737A643-AFD2-47C8-9868-C6879FB2D89AQ47861990-0F76FB8F-0A01-4CB8-AD63-205423D4D781Q48558308-1B163E0B-546B-469F-ABB7-AAF6B62EA497Q50887109-42F2A4E5-60DF-4BF7-BA4C-C38B427BC893Q55258745-3CD6B18C-FF5E-4DC2-B578-ECD0F547F066
P2860
Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@ast
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@en
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@nl
type
label
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@ast
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@en
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@nl
prefLabel
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@ast
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@en
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@nl
P2093
P1433
P1476
Safety and efficacy of desmote ...... cebo-controlled phase 3 trial.
@en
P2093
Antonio E Davalos
Ashfaq Shuaib
Bjørn A Grønning
DIAS-3 Investigators
Gabriela M Ravn
Gary A Ford
Gregory W Albers
James Grotta
Jens-Kristian S Jensen
Ku-Chou Chang
P304
P356
10.1016/S1474-4422(15)00047-2
P577
2015-04-30T00:00:00Z